Johnson & Johnson - JNJ STOCK NEWS

Revelations have emerged regarding Johnson & Johnson (NYSE: JNJ) funding unethical experiments on prisoners during the 1960s, linking to the ongoing controversy over its talc-based products. The experiments involved primarily African-American inmates and raised concerns about the company’s knowledge of the cancer risks associated with its talc products like Johnson's Baby Powder. With the company attempting to limit jury trials through a bankruptcy move, many cancer victims are now seeking justice through litigation. Legal experts call for new laws to prevent corporations from evading liabilities through bankruptcy.

Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.

Johnson & Johnson (NYSE: JNJ) has appointed Darius Adamczyk, Chairman and CEO of Honeywell, to its Board of Directors, effective February 15, 2022. Adamczyk is recognized for his extensive business leadership and commitment to sustainability and innovation. His appointment is expected to enhance the board's diverse expertise and support JNJ's focus on creating healthier communities and delivering transformative health solutions. Adamczyk expressed his honor to join JNJ at a crucial time, emphasizing the company's values-driven mission to improve lives and create long-term stakeholder value.

Johnson & Johnson (NYSE: JNJ) will attend the Raymond James 43rd Annual Institutional Investors Conference on March 8, 2022. Joseph J. Wolk, Executive Vice President and CFO, will speak at 1:05 p.m. ET. Investors can view the session via a webcast on their official website, www.investor.jnj.com. A replay will be accessible approximately 48 hours after the live event.

Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on March 7, 2022, at 9:10 a.m. (Eastern Time). Mathai Mammen, Executive VP of Pharmaceuticals R&D, will represent the company. Investors and interested parties can access the conference call via the Johnson & Johnson website. A webcast and podcast replay will be available approximately 48 hours after the live event.

Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on February 23, 2022. The session will feature Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, presenting at 11:00 a.m. ET. Interested investors can access the conference via the Johnson & Johnson website. Following the live event, a webcast and podcast replay will be available approximately 48 hours later.

Johnson & Johnson (NYSE: JNJ) reported a robust performance for Q4 and full-year 2021. Reported sales reached $24.8 billion in Q4, a 10.4% increase, and $93.8 billion for the year, up 13.6%. Net earnings surged by 172.5% in Q4 to $4.7 billion, while full-year net earnings rose 41.9% to $20.9 billion. Adjusted operational sales growth was notable in Pharmaceuticals (13.6%) and Medical Devices (16.8%), despite supply constraints in Consumer Health. New product approvals and a planned separation of the Consumer Health business were also highlighted as key strategic moves for future growth.

On January 6, 2022, Johnson & Johnson (NYSE: JNJ) released findings from the largest study on COVID-19 vaccine durability in the U.S., highlighting that a single dose of their vaccine provides long-term protection for up to six months. The study, conducted with leading institutions, confirmed an approximately 80% effectiveness against hospitalizations. Notable results included no waning protection against ICU admissions and a modest increase in breakthrough infections after month four. This research positions the Johnson & Johnson vaccine as a viable option amid evolving COVID-19 variants.

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the first quarter of 2022. This dividend payment is scheduled for March 8, 2022, to shareholders on record as of February 22, 2022, with an ex-dividend date of February 18, 2022. The announcement underscores the company's commitment to returning value to its shareholders while continuing its mission to improve health outcomes globally.